N
N

Novartis

技術摘要

指標價值趨勢
指標價值趨勢
指標價值趨勢
指標S3S2S1PR1R2R3

財經新聞

Big Pharma bets on AI to speed up clinical trials

INSIGHT-Big Pharma bets on AI to speed up clinical trials Repeats for additional subscribers By Natalie Grover and Martin Coulter LONDON, Sept 22 (Reuters) - Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.
A
B
N
R

Intel antitrust lawyer joins law firm Arnold & Porter in Washington

Intel antitrust lawyer joins law firm Arnold & Porter in Washington By David Thomas Sept 21 (Reuters) - U.S. law firm Arnold & Porter Kaye Scholer said Thursday it has hired the leader of U.S. chipmaker Intel's INTC.O global M&A regulatory practice for its own antitrust practice. David Emanuelson has joined Arnold & Porter's Washington, D.C., office as a partner, the firm said.
I
N

China's BeiGene falls on terminating cancer drug deal with Novartis

BUZZ-China's BeiGene falls on terminating cancer drug deal with Novartis ** Hong Kong shares of Chinese oncology medicines developer BeiGene Ltd 6160.HK fall as much as 6% to HK$119.40, their lowest since Sept 11 ** Stock on course to snap three straight sessions of gain and for biggest one-day pct decline since Aug 7, if losses hold ** Shanghai-li
N

Novartis AG Novartis And Beigene Have Mutually Agreed To Terminate The Collaboration And License Agreement For Tislelizumab

BRIEF-Novartis AG Novartis And Beigene Have Mutually Agreed To Terminate The Collaboration And License Agreement For Tislelizumab Sept 19 (Reuters) - Beigene Ltd 6160.HK : NOVARTIS AG: NOVARTIS AND BEIGENE, LTD. HAVE MUTUALLY AGREED TO TERMINATE THE COLLABORATION AND LICENSE AGREEMENT FOR TISLELIZUMAB NOVARTIS AG: WITH TERMINATION, BEIGENE WILL RE-
N

BeiGene to go solo with cancer drug after Novartis deal termination

UPDATE 3-BeiGene to go solo with cancer drug after Novartis deal termination Adds Novartis statement in paragraphs 6 and 7, BeiGene comments in paragraph 9, analyst's comment in paragraph 10 By Sriparna Roy Sept 19 (Reuters) - BeiGene 6160.HK and Swiss drugmaker Novartis NOVN.S have terminated a 2021 deal to jointly develop the Hong Kong-listed company's cancer drug, the companies said on Tuesday, marking the second such discontinuation in just over two months.
N

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明